Fitxers
Tipus de document
ArticleVersió
Versió publicadaData de publicació
Llicència de publicació
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/230344
Response to mepolizumab according to disease manifestations in patients with eosinophilic granulomatosis with polyangiitis
Títol de la revista
Director/Tutor
ISSN de la revista
Títol del volum
Recurs relacionat
Resum
Among 56 patients with EGPA regularly controlled at our department, 11 patients were treated with mepolizumab because of corticodependence and unsatisfactory disease control. The mean time of treatment was 38 months (range: 3-66 months). Patients with persistent symptoms improved their asthma control, but 3 of them persisted with recurrent ENT symptoms in spite of treatment with mepolizumab. None of the patients developed vasculitic manifestations (cutaneous, neurological, gastrointestinal, renal) during treatment. All patients achieved a Birmingham Vasculitis Activity Score (BVAS) of 0 points at 12 months or earlier. In general, patients reduced the number of flares, which tended to be milder, and all related to asthma or ENT manifestations. The improvement in disease activity allowed notable glucocorticoid tapering.
Matèries
Matèries (anglès)
Citació
Citació
RÍOS GARCÉS, Roberto, et al. Response to mepolizumab according to disease manifestations in patients with eosinophilic granulomatosis with polyangiitis. European Journal Of Internal Medicine. 2022. ISSN 0953-6205. [consulted: 25 of July of 2026]. Available at: https://hdl.handle.net/2445/230344